• Consensus Rating: Moderate Buy
  • Consensus Price Target: $81.00
  • Forecasted Upside: 1.01%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$80.19
▼ -0.22 (-0.27%)

This chart shows the closing price for TECH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bio-Techne Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TECH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TECH

Analyst Price Target is $81.00
▲ +1.01% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Bio-Techne in the last 3 months. The average price target is $81.00, with a high forecast of $95.00 and a low forecast of $65.00. The average price target represents a 1.01% upside from the last price of $80.19.

This chart shows the closing price for TECH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 investment analysts is to moderate buy stock in Bio-Techne. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/30/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/28/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/29/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/27/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/25/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/23/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/23/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/22/2024CitigroupDowngradeBuy ➝ Neutral$85.00Low
5/2/2024BenchmarkReiterated RatingBuy ➝ Buy$95.00Low
5/2/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$73.00 ➝ $81.00Low
4/18/2024Deutsche Bank AktiengesellschaftLower TargetBuy ➝ Buy$85.00 ➝ $82.00Low
2/8/2024ScotiabankInitiated CoverageSector Outperform$80.00Low
2/2/2024StephensLower TargetOverweight ➝ Overweight$92.00 ➝ $87.00Low
2/2/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$85.00 ➝ $75.00Low
2/2/2024Stifel NicolausDowngradeBuy ➝ Hold$65.00Low
12/7/2023UBS GroupInitiated CoverageBuy$80.00Low
11/2/2023Stifel NicolausLower TargetBuy ➝ Buy$104.00 ➝ $65.00Low
11/1/2023CitigroupLower TargetBuy ➝ Buy$100.00 ➝ $80.00Low
11/1/2023Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$85.00 ➝ $83.00Low
11/1/2023KeyCorpLower TargetOverweight ➝ Overweight$115.00 ➝ $80.00Low
9/12/2023Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$86.00Low
8/28/2023William BlairInitiated CoverageOutperformLow
8/18/2023BenchmarkReiterated RatingBuy ➝ Buy$120.00Low
8/9/2023StephensReiterated RatingOverweight ➝ Overweight$100.00N/A
8/9/2023Robert W. BairdLower Target$100.00 ➝ $90.00Low
5/4/2023Robert W. BairdBoost Target$99.00 ➝ $100.00Low
2/6/2023Royal Bank of CanadaLower TargetSector Perform$89.00 ➝ $88.00Low
2/3/2023Robert W. BairdLower Target$111.50 ➝ $99.00Low
2/3/2023KeyCorpLower TargetOverweight$125.00 ➝ $115.00Low
2/3/2023SVB LeerinkLower TargetOutperform$125.00 ➝ $110.00Low
2/3/2023BenchmarkReiterated RatingBuy$120.00N/A
1/10/2023Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$90.00Low
12/13/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy$100.00Low
12/12/2022CitigroupUpgradeNeutral ➝ Buy$81.25 ➝ $100.00Low
12/6/2022Royal Bank of CanadaInitiated CoverageSector Perform$89.00Low
12/5/2022StephensLower TargetOverweight ➝ Overweight$105.00Low
11/2/2022Craig HallumLower Target$125.25 ➝ $104.75Low
11/2/2022BenchmarkLower Target$135.00 ➝ $120.00Low
11/2/2022Robert W. BairdLower Target$117.50 ➝ $111.50N/A
11/2/2022SVB LeerinkLower TargetOutperform$137.50 ➝ $125.00Low
8/24/2022Credit Suisse GroupInitiated CoverageOutperform$116.25Low
8/16/2022Wells Fargo & CompanyLower TargetUnderweight$92.50 ➝ $90.00Low
8/5/2022Robert W. BairdLower Target$125.00 ➝ $117.50Low
8/5/2022StephensLower TargetOverweight$125.00 ➝ $120.00Low
5/5/2022Robert W. BairdLower Target$130.00 ➝ $125.00High
5/5/2022KeyCorpLower Target$150.00 ➝ $125.00High
4/25/2022Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$100.00 ➝ $92.50Medium
2/2/2022SVB LeerinkBoost TargetOutperform$132.50 ➝ $143.75High
11/3/2021Robert W. BairdBoost TargetOutperform$130.50 ➝ $137.00High
8/24/2021ArgusBoost TargetBuy$122.50 ➝ $135.00High
8/6/2021Robert W. BairdBoost TargetOutperform$107.50 ➝ $130.50High
8/5/2021BenchmarkBoost TargetBuy$120.00 ➝ $135.00High
6/29/2021SVB LeerinkBoost TargetOutperform$112.50 ➝ $120.00Low
6/18/2021ArgusBoost TargetBuy$110.00 ➝ $122.50High
5/7/2021Robert W. BairdBoost TargetOutperform$102.50 ➝ $107.50Medium
3/8/2021StephensUpgradeEqual Weight ➝ Overweight$95.00 ➝ $106.25High
2/23/2021Stifel NicolausUpgradeHold ➝ Buy$108.75Low
2/3/2021CitigroupBoost TargetNeutral$77.50 ➝ $100.00Low
2/3/2021Craig HallumBoost TargetBuy$88.00 ➝ $110.00Medium
1/25/2021BenchmarkBoost TargetBuy$80.00 ➝ $102.50Low
11/9/2020KeyCorpInitiated CoverageSector Weight ➝ Sector Weight$85.00Low
11/6/2020Robert W. BairdBoost TargetOutperform$72.25 ➝ $80.00Low
11/6/2020SVB LeerinkBoost TargetOutperform$71.25 ➝ $80.00Low
9/30/2020Atlantic SecuritiesInitiated CoverageOverweight$91.25Low
8/5/2020SVB LeerinkBoost TargetOutperform$66.25 ➝ $71.25Medium
8/4/2020Wells Fargo & CompanyReiterated RatingHoldMedium
8/4/2020Craig HallumUpgradeHold ➝ Buy$52.75 ➝ $82.00Medium
7/15/2020StephensDowngradeOverweight ➝ Equal Weight$63.25 ➝ $68.25High
6/18/2020CitigroupBoost TargetNeutral$57.50 ➝ $65.00Low
5/27/2020Stifel NicolausDowngradeBuy ➝ Hold$61.25 ➝ $65.00Medium
5/14/2020BenchmarkInitiated CoverageBuy$72.50Low
5/1/2020StephensBoost TargetOverweight$57.50 ➝ $63.25High
5/1/2020Wells Fargo & CompanyBoost TargetEqual Weight$47.50 ➝ $55.00High
5/1/2020Stifel NicolausBoost TargetBuy$52.50 ➝ $61.25Medium
4/20/2020CitigroupBoost TargetNeutral$43.75 ➝ $53.75Low
4/20/2020Craig HallumLower TargetBuy$54.50 ➝ $52.75Medium
4/2/2020Stifel NicolausLower TargetBuy$58.75 ➝ $52.50Medium
3/30/2020Wells Fargo & CompanyLower TargetEqual Weight$56.25 ➝ $47.50High
3/20/2020CitigroupLower TargetNeutral$56.25 ➝ $43.75High
2/24/2020Eight CapitalDowngradeBuy ➝ NeutralLow
2/5/2020Robert W. BairdBoost TargetOutperform$55.50 ➝ $57.50Low
2/5/2020CitigroupLower TargetNeutral$58.75 ➝ $56.25Low
1/8/2020StephensInitiated CoverageOverweightLow
1/7/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$57.50Low
1/6/2020CitigroupInitiated CoverageNeutral$58.75Low
11/14/2019Stifel NicolausInitiated CoverageBuy$58.75High
9/26/2019SVB LeerinkReiterated RatingOutperform$57.50 ➝ $60.00Low
7/2/2019Janney Montgomery ScottUpgradeNeutral ➝ Buy$50.00 ➝ $67.50High
(Data available from 5/24/2019 forward)

News Sentiment Rating

0.78 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 13 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/26/2023
  • 4 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/25/2023
  • 15 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/25/2023
  • 15 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/24/2024
  • 21 very positive mentions
  • 23 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
2/23/2024
  • 18 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2024
  • 15 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/23/2024
  • 23 very positive mentions
  • 31 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/23/2024

Current Sentiment

  • 23 very positive mentions
  • 31 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Bio-Techne logo
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Read More

Today's Range

Now: $80.19
Low: $79.95
High: $81.03

50 Day Range

MA: $71.73
Low: $62.12
High: $84.15

52 Week Range

Now: $80.19
Low: $51.79
High: $89.91

Volume

117,566 shs

Average Volume

1,098,897 shs

Market Capitalization

$12.64 billion

P/E Ratio

63.64

Dividend Yield

0.39%

Beta

1.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Bio-Techne?

The following Wall Street analysts have issued stock ratings on Bio-Techne in the last year: Benchmark Co., Citigroup Inc., Deutsche Bank Aktiengesellschaft, KeyCorp, Robert W. Baird, Royal Bank of Canada, Scotiabank, Stephens, Stifel Nicolaus, StockNews.com, TheStreet, UBS Group AG, and William Blair.
View the latest analyst ratings for TECH.

What is the current price target for Bio-Techne?

10 Wall Street analysts have set twelve-month price targets for Bio-Techne in the last year. Their average twelve-month price target is $81.00, suggesting a possible upside of 0.7%. Benchmark Co. has the highest price target set, predicting TECH will reach $95.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $65.00 for Bio-Techne in the next year.
View the latest price targets for TECH.

What is the current consensus analyst rating for Bio-Techne?

Bio-Techne currently has 3 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TECH.

What other companies compete with Bio-Techne?

How do I contact Bio-Techne's investor relations team?

Bio-Techne's physical mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company's listed phone number is (612) 379-8854 and its investor relations email address is [email protected]. The official website for Bio-Techne is www.bio-techne.com. Learn More about contacing Bio-Techne investor relations.